Category: Intellectual property
-
Start-Up Developing Gene Therapies Lands $45M in Early Funds
12 February 2014. Voyager Therapeutics, a new start-up in Cambridge, Massachusetts creating gene therapies for disorders of the central nervous system, gained $45 million in first-round financing. Third Rock Ventures, a venture capital company specializing in life science enterprises, provided the funds for the company founded by researchers at University of Massachusetts Medical School, University…
-
European Venture Licenses Biotech Drought-Resistant Traits
Genective, a joint venture between German and French seed companies to develop new corn varieties, is licensing engineered gene science from the biotechnology company Arcadia Biosciences Inc. in Davis, California. Arcadia Biosciences will receive initial, milestone, and sales royalty payments under the agreement, but the dollar amount of the deal was not disclosed. Arcadia Biosciences…
-
South Carolina Partnership Licenses First Technology
SCRA, a South Carolina state business investment organization in Columbia, and TAO Life Sciences, a medical device commercialization company in Greenville, say they completed their first licensing deal for a chest drainage tube device invented by students at Clemson University. Financial aspects of the licensing agreement were not disclosed. Bioengineering students at Clemson University designed…
-
Heart Vessel Surgical Glue Shown Effective in Animal Tests
Surgeons and biomedical engineers at Boston Children’s and Brigham and Women’s hospitals and Massachusetts Institute of Technology, developed a non-toxic, biocompatible surgical glue that in tests with pigs patches heart defects, such as those in large blood vessels. The team led by Boston Children’s Pedro del Nido and Jeffrey Karp of Brigham and Women’s Hospital…
-
Start-Up Licenses UMass Cancer Immunotherapy Technology
Agalimmune Ltd., a new start-up enterprise in London, U.K. and Irvine, California, licensed research discoveries from University of Massachusetts Medical School in Worcester to develop treatments for solid tumors that harness the power of the patient’s immune system. Financial details of the agreement were not disclosed. The technology licensed from UMass, called Alphaject by the…
-
Patent Awarded for Bone Graft Material Production Process
Bacterin International Holdings, a medical device company in Belgrade, Montana received a patent for its technology to produce a form of human bone material suitable for bone grafts that promote regeneration of bone tissue. The U.S. Patent and Trademark Office yesterday issued patent 8,574,825 to seven inventors, including Gregory Juda, Bacterin’s chief scientist, and Steven…
-
GlaxoSmithKline Names Academic Drug Discovery Partners
The pharmaceutical company GlaxoSmithKline named 10 academic scientists to its Discovery Fast Track competition that aims to turn university research findings into new therapies. The researchers will get access to GlaxoSmithKline’s facilities and materials to accelerate the drug discovery process, potentially leading to a collaboration to further develop the compound. Discovery Fast Track began in…
-
Novartis Licenses University Stem Cell Transplant Technology
The global pharmaceutical company Novartis, based in Switzerland, is licensing research conducted at University of Louisville to help transplant patients better tolerate donated kidneys. Financial aspects of the agreement between Novartis and the Louisville biotechnology company Regenerex LLC, the original licensee and completed last month, were not disclosed. Regenerex is the company founded by Suzanne…
-
Pfizer Licenses University Institute’s Obesity Research
The global pharmaceutical company Pfizer is funding research at Université de Montréal in Quebec, Canada to identify cellular pathways in genetic defects leading to therapies for early-onset morbid obesity. Financial aspects of the collaboration, which gives Pfizer a license to commercially develop results of the research, were not disclosed. Pfizer is funding and licensing research…
-
Who’s a Patent Troll? You’ll be Surprised by the Answer
Nobody likes patent trolls, the “non-practicing entities” accused of filing lawsuits with questionable infringement claims aimed at extorting settlements from companies just trying to do business. A conference today in Washington, D.C. sponsored by Innovation Alliance — a group promoting a strong U.S. patent system — featured a panelist who would under some definitions be…